Document is current
Any future updates will be listed below
-
Authors
Mehta, Rohtesh S. https://orcid.org/0000-0002-8532-544X
Ali, Haris https://orcid.org/0000-0002-9728-7292
Dai, Yang
Yao, Bert
Overman, Bethany
Ratanatharathorn, Voravit
Gill, Saar
Socié, Gerard https://orcid.org/0000-0002-2114-7533
Anderson, Kevin
Cahn, Jean Yves
Mujeebuddin, Arshad
Champlin, Richard https://orcid.org/0000-0002-4314-5037
Shpall, Elizabeth
Holtan, Shernan G.
Alousi, Amin https://orcid.org/0000-0002-2498-8573
-
Funding
Funding for this research was provided by:
Alexion Pharmaceuticals (NA, N/A, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)
- License Information
-
More Information
Article History
Received: 1 April 2022
Revised: 29 March 2023
Accepted: 19 April 2023
First Online: 18 May 2023
Competing interests
: RSM received research funding from CSLBehring, Kadmon and Incyte. HA has received consulting fees from Incyte and BMS. YD, and AM are employees and stockholders of Alexion Pharmaceuticals Inc (now Alexion, Astrazeneca Rare Disease). BY and KA were employees and stockholders of Alexion Pharmaceuticals Inc during the development phase of this manuscript. GS received a research grant from Alexion Pharamceuticals. SH has received consulting fees/honoraria from Incyte, Generon and served participated in a Data Safety Monitoring Board/Advisory Board for CSl Behring. JYC declares receiving honoraria for participating in an Advisory Board for Alexion Pharmaceuticals. BO, VR, SG, RC, and ES declare no competing interests. AA has received research support, and honoraria for participating in an Advisory Board for Alexion Pharmaceuticals.
